Aggregate Distributional Cost-Effectiveness Analysis of Health Technologies

Abstract

Background: Health inequalities can be partially addressed through the range of treatments funded by health systems. Nevertheless, although health technology assessment agencies assess the overall balance of health benefits and costs, no quantitative assessment of health inequality impact is consistently undertaken.Objectives: To assess the inequality impact of technologies recommended under the NICE single technology appraisal process from 2012 to 2014 using an aggregate distributional cost-effectiveness framework.Methods: Data on health benefits, costs, and patient populations were extracted from the NICE website. Benefits for each technology were distributed to social groups using the observed socioeconomic distribution of hospital utilization for the targeted disease. Inequality measures and estimates of cost-effectiveness were compared using the health inequality impact plane and combined using social welfare indices.Results: Twenty-seven interventions were evaluated. Fourteen interventions were estimated to increase population health and reduce health inequality, 8 to reduce population health and increase health inequality, and 5 to increase health and increase health inequality. Among the latter 5, social welfare analysis, using inequality aversion parameters reflecting high concern for inequality, indicated that the health gain outweighs the negative health inequality impact. Conclusions:The methods proposed offer a way of estimating the health inequality impacts of new health technologies. The methods do not allow for differences in technology-specific utilization and health benefits, but require less resources and data than conducting full distributional cost-effectiveness analysis. They can provide useful quantitative information to help policy makers consider how far new technologies are likely to reduce or increase health inequalities.

Principles of Economic Evaluation in a Pandemic Setting: An Expert Panel Discussion on Value Assessment During the Coronavirus Disease 2019 Pandemic

“…The distributional form of cost-effectiveness analysis (DCEA) evaluates interventions with differential impacts on socioeconomic subgroups and compares the magnitude in each group [26,27]. In lieu of a full DCEA, which would require trial data or a decision-analytic model to empirically inform the distribution of effects, Love-Koh et al describe an aggregate DCEA for health technologies that rolls up existing data alongside a measure of inequality [28]. Use of the DCEA model can help value therapies based on reductions in health inequities among specified at-risk subgroups.…”

Distributional Cost-Effectiveness Analysis Comes of Age

“…These combine aggregate outputs from standard cost-effectiveness analysis with information about distributions of a relevant disease or risk factor and utilization of a relevant category of care. 22,26 This can provide useful prima facie information about equity impact, even though there is no detailed modeling.…”

Methods to promote equity in health resource allocation in low- and middle-income countries: an overview

“…Health inequality is modelled prior to an intervention, and the impact of the intervention is modelled to generate a hypothetical 'post-intervention' distribution. Although a full DCEA approach uses bespoke estimates of health benefits and costs from a mathematical model, an aggregate, less data intensive approach has also been developed that allocates health benefits to equityrelevant groups based on their share of healthcare utilisation or disease prevalence [64,65]. Health-related social welfare indices are then applied to evaluate the changes in total health and health inequality in instances where a trade-off occurs (i.e.…”